Clinical Trial Update: A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM [Phase 2]

View source ↗

Summary

This Phase 2 trial comparing GZR101 with IDegAsp in insulin-naïve or insulin-treated adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GZR101
• IDegAsp (insulin degludec/insulin aspart)

Snippet

Sponsor: Gan and Lee Pharmaceuticals, USA | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED